Neurogene Inc. Interest Income (Expense), Nonoperating, Net
Neurogene Inc. (NGNE) reported Interest Income (Expense), Nonoperating, Net of $142.00 thousand for the 3-month period ending 2016-09-30, per its 10-Q filed 2016-11-09.
Discontinued › Income Statement › Other Income
us-gaap:InterestIncomeExpenseNonoperatingNet · last filed 2016-11-09
- Neurogene Inc. interest income (expense), nonoperating, net for the quarter ending 2016-09-30 was $142.00K, a 1477.78% increase year-over-year.
- Neurogene Inc. interest income (expense), nonoperating, net for the quarter ending 2016-06-30 was $128.00K, a 966.67% increase year-over-year.
- Neurogene Inc. interest income (expense), nonoperating, net for the quarter ending 2016-03-31 was $121.00K, a 706.67% increase year-over-year.
- Neurogene Inc. interest income (expense), nonoperating, net for the quarter ending 2015-09-30 was $9.00K.
| Period end | Interest Income (Expense), Nonoperating, Net 3 month | Interest Income (Expense), Nonoperating, Net 6 month | Interest Income (Expense), Nonoperating, Net 9 month |
|---|---|---|---|
| 2016-09-30 | $142.00K 10-Q · filed 2016-11-09 | $270.00K derived: sum of 2 quarters · filed 2016-11-09 | $391.00K 10-Q · filed 2016-11-09 |
| 2016-06-30 | $128.00K 10-Q · filed 2016-08-04 | $249.00K 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $121.00K 10-Q · filed 2016-05-10 | ||
| 2015-09-30 | $9.00K 10-Q · filed 2016-11-09 | $21.00K derived: sum of 2 quarters · filed 2016-11-09 | $36.00K 10-Q · filed 2016-11-09 |
| 2015-06-30 | $12.00K 10-Q · filed 2016-08-04 | $27.00K 10-Q · filed 2016-08-04 | |
| 2015-03-31 | $15.00K 10-Q · filed 2016-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |